Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Non-segmental Vitiligo

In brief

This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study

Key facts

Study ID

NCT07172347

Run by

Jiangsu vcare pharmaceutical technology co., LTD

People needed

120

Starts

2025-10-31

Expected to finish

2027-08-30

Last updated by the study team

2026-01-02

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol.
• The subject is between 18 and 70 years of age (including borderline values) , regardless of gender.

You may not qualify if…

• Pregnant or lactating women, or subjects with pregnancy or lactation plans during the study period.
• All hair in the vitiligo area on the face is white.
• Those who are known or suspected to be allergic to the main ingredients and excipients of VC005 or similar drugs.
• Subjects who have previously received depigmentation treatment.
• Subjects who have received experimental drug administration or participated in device clinical trials within the first month or 5 half lives (whichever is longer) prior to randomization.

Where it is running

• The Peking University People's Hospital — Beijing, Beijng, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.